|
ICON's medical and regulatory staff can provide strategies and
solutions to navigate through regulatory "grey areas" and ensure risk
minimization activities are implemented effectively |
|
Our Drug Safety and Pharmacovigilance services are centralized at
six global safety hubs located in the US, UK, Germany, India,
Argentina, and Singapore |
|
ICON's Lifecycle Sciences Group has been involved in global registry
study design and implementation for almost 20 years |
|
ICON's Lifecycle Sciences Group have developed almost 800
observational research peer-reviewed publications across all
therapeutic areas |
|
We have global registry program experience that ranges from a single
center to over 2,000 centers with patient populations ranging from 20
to over two million across all major therapeutic areas. They include:
- Orphan disease programs to gain a better understanding of the
natural history, treatment patterns and outcomes associated with
various treatment
- Disease and product registries designed to collect safety data based
on real-world treatment of patients
- Studies designed to complement the results from a clinical trial
- Post-marketing regulatory commitments
- Comparative Effectiveness studies comparing one or more medical
or surgical interventions
|
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology
and medical device industries. We specialize in the strategic development, management and analysis
of programs that support clinical developmentâfrom compound selection to Phase I-IV clinical studies.
ICON currently has over 7,000 employees, operating from 68 locations in 38 countries.
Further information is available at www.iconplc.com |
